Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1. El-Khoueiry, A.B.
2. Sangro, B.
3. Yau, T.
4. Crocenzi, T.S.
5. Kudo, M.
6. Hsu, C.
7. Kim, T.-Y.
8. Choo, S.-P.
9. Trojan, J.
10. Welling, T.H.
11. Meyer, T.
12. Kang, Y.-K.
13. Yeo, W.
14. Chopra, A.
15. Anderson, J.
16. dela Cruz, C.
17. Lang, L.
18. Neely, J.
19. Tang, H.
20. Dastani, H.B.
21. Melero, I.